China Pharmaceutical Company Shanghai Henlius Biotech Shareholders Reject China Conglomerate Fosun International $1.72 Billion Buyout Offer, Fosun Pharmaceutical Currently Holds 59.6% Shareholding in Shanghai Henlius Biotech & Offered HKD 24.6 Per Share in Buyout, Current Market Value at $1.1 Billion, Share Price -31% YTD, +10% in Last 1 Year & -60% in Last 5 Years, Shanghai Henlius Biotech IPO in 2019 on Hong Kong Exchange, Founded in 2010 by Fosun Pharmaceutical & International Scientists Including CEO Dr Scott Liu
23rd January 2025 | Hong Kong
China pharmaceutical company Shanghai Henlius Biotech shareholders have rejected China conglomerate Fosun International $1.72 billion buyout offer. Fosun Pharmaceutical currently holds 59.6% shareholding in Shanghai Henlius Biotech, and offered HKD 24.6 per share in the buyout. Shanghai Henlius Biotech current market value is at $1.1 billion, with share price -31% YTD, +10% in the last 1 year & -60% in the last 5 years. Shanghai Henlius Biotech IPO in 2019 on Hong Kong Exchange (HKEX), and was founded in 2010 by Fosun Pharmaceutical & international scientists including CEO Dr Scott Liu. Profile – Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 3 have been approved for marketing in overseas markets, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI(bevacizumab), HANSIZHUANG(serplulimab), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.
“ China Pharmaceutical Company Shanghai Henlius Biotech Shareholders Reject China Conglomerate Fosun International $1.72 Billion Buyout Offer, Fosun Pharmaceutical Currently Holds 59.6% Shareholding in Shanghai Henlius Biotech & Offered HKD 24.6 Per Share in Buyout, Current Market Value at $1.1 Billion, Share Price -31% YTD, +10% in Last 1 Year & -60% in Last 5 Years, Shanghai Henlius Biotech IPO in 2019 on Hong Kong Exchange, Founded in 2010 by Fosun Pharmaceutical & International Scientists Including CEO Dr Scott Liu “
China Pharmaceutical Company Shanghai Henlius Biotech Shareholders Reject China Conglomerate Fosun International $1.72 Billion Buyout Offer, Fosun Pharmaceutical Currently Holds 59.6% Shareholding in Shanghai Henlius Biotech & Offered HKD 24.6 Per Share in Buyout, Current Market Value at $1.1 Billion, Share Price -31% YTD, +10% in Last 1 Year & -60% in Last 5 Years, Shanghai Henlius Biotech IPO in 2019 on Hong Kong Exchange, Founded in 2010 by Fosun Pharmaceutical & International Scientists Including CEO Dr Scott Liu
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
